The quiet science that keeps biologic drugs alive: excipient blends and the analytics behind them

Biopharmaceuticals don’t tolerate stress well. Freeze, shake, warm them a few degrees too far, and proteins unfold, aggregate, or lose potency. That’s why modern formulations are built around excipients (functional inactive ingredients) that stabilize the drug substance during manufacturing, storage, and reconstitution, and why companies lean on orthogonal analytical methods to prove those excipients work.

Non‑reducing sugars like sucrose and trehalose are classic cryo‑/lyoprotectants (they protect during freezing and drying), forming an amorphous glass that “locks” proteins in place (pmc.ncbi.nlm.nih.gov). Industry data show ~24.4% of approved biologics include sucrose (pmc.ncbi.nlm.nih.gov). Polyols like mannitol (used in ~20.9% of formulations, pmc.ncbi.nlm.nih.gov) and sorbitol also stabilize proteins by hydrogen bonding and lowering water activity.

Formulators don’t pick excipients on faith. They measure glass transition temperature (T_g, the point where an amorphous solid shifts from glassy to rubbery), track monomer loss and aggregates, and scrutinize “cake” structure after lyophilization (freeze‑drying). The result is a data‑driven balancing act that has quietly become a competitive edge as the protein therapeutics market is projected to grow from ~$517 billion in 2024 to ~$762 billion by 2029 (www.pharmaexcipients.com).

Excipient functions and usage trends

In practice, stabilizers, buffers, bulking agents, surfactants, and supportive excipients each counter specific degradation modes. Sucrose and trehalose raise T_g, reduce ice‑interface stress, and help preserve tertiary structure. Amino acids play multiple roles: glycine is a common bulking agent that often crystallizes during freezing to improve cake appearance, and even partially amorphous glycine greatly enhanced long‑term IgG stability versus sucrose alone in one study (pubmed.ncbi.nlm.nih.gov). By contrast, the same study found mannitol (fully crystalline) had little stabilizing effect on aggregation (pubmed.ncbi.nlm.nih.gov), underscoring how excipient physical state is critical.

Buffers maintain pH during freeze‑concentration; most monoclonal antibody (mAb) formulations use histidine buffer at ~pH 6 to resist freeze‑induced pH shifts. Empliciti’s approved lyophilizate uses citrate/citric acid as a freeze‑stable buffer and sucrose; labels confirm polysorbate 80 (PS‑80) is present at ~4–4.4 mg per dose and sucrose at 510–660 mg per vial (www.drugs.com).

Surfactants are vital to suppress interfacial denaturation. Polysorbates (especially PS‑80) are used in ~28.7% of biologics (pmc.ncbi.nlm.nih.gov), and salts like NaCl appear in ~38% (pmc.ncbi.nlm.nih.gov). A typical biologic formulation contains ~4–5 excipients (pmc.ncbi.nlm.nih.gov). Notably, >60% of marketed biologics today require lyophilization (www.sciencedirect.com), because the dry solid tolerates room‑temperature storage and transport better than liquid.

Bulking agents and cake physics

Bulking agents build the lyophilized cake framework. Glycine may crystallize during freezing (increasing cake rigidity) yet leave an amorphous fraction that stabilizes protein (pubmed.ncbi.nlm.nih.gov). Mannitol typically crystallizes fully, which reduces moisture uptake but, in that same study, added little extra stabilization against aggregation (pubmed.ncbi.nlm.nih.gov). Choice always balances cake appearance versus T_g.

Excipients can be blended to change the rules. High‑molecular excipients like polyvinylpyrrolidone (PVP) or cyclodextrins raise T_g and improve freeze‑drying robustness. Adding 2‑hydroxypropyl‑β‑cyclodextrin (HP‑β‑CD) to a sucrose matrix allowed a lyophilized antibody to be stored at 40 °C for 9 months with excellent cake appearance and monomer recovery—and the mixed formulation tolerated a much faster freeze/dry cycle because T_g and collapse temperature (T_c, above which the frozen matrix loses structure during drying) were higher (pubmed.ncbi.nlm.nih.gov). In development work, cyclodextrins and PVP have enabled “single‑step” aggressive lyophilization protocols that cut cycle time by ~30–50% without compromising stability (pubmed.ncbi.nlm.nih.gov).

There are nuanced chemical effects too. One study showed that adding just 5% glycine to a sucrose formulation cut antibody deamidation by over 50% while preserving the cake (pubmed.ncbi.nlm.nih.gov). These examples underline that excipient blending can dramatically extend shelf life or reduce costs.

Surfactants, salts, and protective additives

Polysorbate 20/80 (PS‑20/PS‑80) form a protective layer at air/water or ice interfaces and are included in nearly one‑third of biologics (pmc.ncbi.nlm.nih.gov). Note: polysorbates can oxidize, so some formulations are exploring alternatives like HP‑β‑CD or amino acids (pmc.ncbi.nlm.nih.gov).

Salts (e.g., NaCl) and sugars like mannitol adjust tonicity. Antioxidants or chelators such as methionine and EDTA (ethylenediaminetetraacetic acid) mitigate oxidation by scavenging reactive species or metal ions. Silicone oils or surfactants can also prevent agitation‑induced foaming. In practice, each excipient choice aligns to a specific degradation mechanism, and approved labels—Empliciti’s among them—reflect this with sucrose, a citrate buffer, and PS‑80 listed as inactive ingredients (www.drugs.com).

Analytical techniques for stability assessment

Orthogonal methods are standard. Size‑Exclusion Chromatography (SEC, separates species by hydrodynamic size) is the workhorse for monomer vs aggregate quantitation, while Dynamic Light Scattering (DLS, laser‑based sizing of nanoparticles) detects sub‑micron particles. A recent review notes SEC and DLS are “the most reliable and widely used” methods to detect aggregates, and they complement each other (pmc.ncbi.nlm.nih.gov). Accelerated stability runs often report % monomer (SEC) and particle counts (light obscuration/DLS) to flag aggregation.

Spectroscopic and structural probes track conformation. Fourier‑Transform Infrared (FTIR) spectroscopy monitors secondary structure in solution and solid states; sharp amide I/II bands indicate intact α‑helix/β‑sheet content, while shifts or broadening signal unfolding (pmc.ncbi.nlm.nih.gov). Circular Dichroism (CD) measures secondary/tertiary structure in solution after reconstitution. Near‑Infrared/Raman can probe conformation in the dry cake. These methods are rapid and non‑destructive; development groups routinely correlate FTIR/CD signals with SEC aggregation metrics (pmc.ncbi.nlm.nih.gov).

Thermal and physical analysis anchors process design. Differential Scanning Calorimetry (DSC) measures T_g and thermal denaturation temperature (T_m), both predictors of shelf stability. DSC also flags excipient crystallization onsets. Dielectric Relaxation Spectroscopy (DRS) and X‑ray Diffraction (XRD) characterize molecular mobility and crystalline vs amorphous content, respectively (pmc.ncbi.nlm.nih.gov). Freeze‑drying microscopy (FDM) determines collapse temperature (T_c) before scale‑up. After drying, cryo‑SEM (scanning electron microscopy at cryogenic temperatures) or simple photography checks cake morphology (shrinkage, collapse, density). Residual moisture is measured by Karl Fischer titration (a chemical method for water content), typically kept <1–3% to prolong stability. In one case study, researchers measured T_c (FDM), T_g (DSC) and cake appearance, and found formulations with higher T_g (e.g., using cyclodextrin) yielded elegant cakes and faster reconstitution (pubmed.ncbi.nlm.nih.gov).

Chemical purity assays quantify degradants. Reversed‑Phase HPLC resolves hydrophobic variants (oxidized or clipped fragments) and peptide maps. Ion‑Exchange HPLC or capillary isoelectric focusing (cIEF) resolves charge variants such as deamidation or isoforms. Mass Spectrometry (MS) provides detailed modification profiles; solid‑state hydrogen/deuterium exchange mass spectrometry (ssHDX‑MS) pinpoints subtle structural changes in the cake that correlate with long‑term stability (pmc.ncbi.nlm.nih.gov).

Biological potency remains the ultimate check. Stability programs include potency assays (e.g., receptor‑binding ELISA and cell‑based efficacy assays) because a stable formulation must retain labeled activity within specifications over time. Loss of potency often parallels increases in aggregates or chemical changes. This is a regulatory requirement (ICH Q5C) and a practical readout of formulation success.

QC rounds out the picture. At each time‑point, teams assess visual appearance (solution clarity, color), pH, osmolarity, protein concentration, sterility, and sub‑visible particulate counts (by light obscuration). Together, these analytics give a comprehensive stability view; one published study, for example, stored lyophilized mAb vials at 5 °C, 25 °C, and 40 °C for 9 months and collected data on color, turbidity, particle count, and SEC monomer content (pubmed.ncbi.nlm.nih.gov). Such multi‑dimensional data support Arrhenius plots (temperature‑accelerated rate modeling) to predict shelf life, and inform real‑time “release” and “shelf” specifications—e.g., a formulation might be acceptable only if aggregation stays <5% over 2 years at 5 °C. In practice, formulation scientists use design‑of‑experiment (DoE) with these analytical readouts to compare excipient options and finalize robust products.

Case labels and usage snapshots

Label data echo the trends. Empliciti’s lyophilized presentation lists sucrose (510–660 mg/vial), a citrate buffer (citric acid/sodium citrate), and PS‑80, with ~4–4.4 mg PS‑80 per dose (www.drugs.com)—a typical lyophilized mAb formula. Across the market, ~29% of biologics use PS‑80 and ~24% use sucrose, ~20.9% use mannitol, and ~38% include NaCl (pmc.ncbi.nlm.nih.gov). Mixing sugars or combining sugars with PVP/dextran can further raise T_g and protect structure (pmc.ncbi.nlm.nih.gov).

As new biologics are created, the need for lyophilization has only grown; >60% of marketed biologics today require it (www.sciencedirect.com). That necessity—combined with the projected growth of the protein therapeutics market from ~$517 billion in 2024 to ~$762 billion by 2029 (www.pharmaexcipients.com)—has turned excipient selection and analytical validation into both a regulatory must‑do and a business imperative.

References

Ionova Y. et al., PLoS ONE 15(6):e0235076 (2020). (pmc.ncbi.nlm.nih.gov)

Bjelošević M. et al., Eur J Pharm Sci 122:292–302 (2018). (pubmed.ncbi.nlm.nih.gov)

Iacocca D.G. et al., AAPS PharmSciTech 11(4):1063–72 (2010). (pubmed.ncbi.nlm.nih.gov)

Empliciti Prescribing Information (BMS, 2024) [Inactive ingredients: citric acid, sodium citrate, sucrose, polysorbate 80]. (www.drugs.com)

Zhao G. et al., J Drug Deliv Sci Technol 100:106089 (2024). (www.sciencedirect.com)

Bolje A., Gobec S., Pharmaceutics 13(4):534 (2021). (pmc.ncbi.nlm.nih.gov)

Bolje A., Gobec S., Pharmaceutics 13(4):534 (2021). (pmc.ncbi.nlm.nih.gov)

Bolje A., Gobec S., Pharmaceutics 13(4):534 (2021). (pmc.ncbi.nlm.nih.gov)

Bolje A., Gobec S., Pharmaceutics 13(4):534 (2021). (pmc.ncbi.nlm.nih.gov)

Miscellaneous (industry data report, Pharma Excipients, 2024). (www.pharmaexcipients.com)